Julien Baruteau
University College London, Great Ormond Street Hospital For Children NHS Foundation Trust, Universite de Toulouse, Great Ormond Street Hospital For Children NHS Trust, Université Paris Descartes
0000-0003-0582-540X
About
I am a Clinician Scientist with a special interest in Inherited Metabolic Diseases. I have chosen rare monogenic diseases as unique models to discover novel biological mechanisms and therapeutic targets for rare and common diseases.
My main research is to understand how the metabolism of arginine and its downstream metabolite nitric oxide (NO), affect the central nervous system from neurodevelopment, to bioenergetics and neurodegeneration. In parallel, I am developing novel therapies for Inherited Metabolic Diseases from small molecules to viral (AAV or lentiviral) and non-viral (lipid nanoparticles encapsulating mRNA, exosomes) gene therapies. I have a special interest in a rare group of diseases called urea cycle defects.
I am clinically active and I am a consultant in the Metabolic Medicine Unit at Great Ormond Street Hospital for Children, London, UK.
My work is supported by the UK Medical Research Council, Action Medical Research, Great Ormond Street Hospital Charity, NIHR GOSH Biomedical Research Centre.
Employment
-
University College London Principal Research Fellow2022 - Present
-
Great Ormond Street Hospital For Children NHS Foundation Trust Honorary Consultant2017 - Present
-
University College London Senior Research Associate2017 - 2022
-
University College London Research Training Fellow2013 - 2014
-
Great Ormond Street Hospital For Children NHS Trust Honorary Clinical Fellow2012 - 2014
Education
-
University College London PhD2013 - 2017
-
Universite de Toulouse Master Degree in Science2010 - 2012
-
Université Paris Descartes InterUniversity Diploma in Inborn Metabolic Diseases2008 - 2010
-
Université Paul Sabatier Medical Doctor, Specialisation in Paediatrics? - 2008
Projects & Funding
Projects & funding information is unavailable.
Publications (65)
- Delivering the Message: Translating mRNA Therapy for Liver Inherited Metabolic Diseases Save
- Macrophage Inhibitor Clodronate Enhances Liver Transduction of Lentiviral but Not Adeno-Associated Viral Vectors or mRNA Lipid Nanoparticles in Neonatal and Juvenile Mice Save
- Gene therapy for urea cycle defects: An update from historical perspectives to future prospects Save
- Liver-directed gene therapy for inherited metabolic diseases. Save
- Mission possible: Gene therapy for inherited metabolic diseases. Save
- mRNA therapy corrects defective glutathione metabolism and restores ureagenesis in preclinical argininosuccinic aciduria. Save
- Ex vivo precision-cut liver slices model disease phenotype and monitor therapeutic response for liver monogenic diseases Save
- Macrophage inhibitor clodronate enhances liver transduction of lentiviral but not AAV vectors or mRNA lipid nanoparticlesin vivo Save
- Prolonged respiratory failure responds to conventional therapy in isolated homocysteine remethylation defects Save
- Three-Country Snapshot of Ornithine Transcarbamylase Deficiency Save